Ultragenyx Pharmaceutical (RARE) Earnings Date, Estimates & Call Transcripts $42.59 -1.89 (-4.25%) Closing price 04:00 PM EasternExtended Trading$42.56 -0.03 (-0.07%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Ultragenyx Pharmaceutical Latest Earnings SummaryUpcoming Q1 Earnings DateMay. 1After Market ClosesEstimatedActual EPS (Feb. 13) -$1.39 Missed By -$0.07 Consensus EPS (Feb. 13) -$1.32 Ultragenyx Pharmaceutical issued Q4 2024 earnings on February 13, 2025, reporting an EPS of -$1.39, which missed analysts' consensus estimates of -$1.32 by $0.07. Quarterly revenue was reported to be $164.88 million, above analysts' expectations of $163.23 million. With a trailing EPS of -$6.34, Ultragenyx Pharmaceutical's earnings are expected to grow next year, from ($5.18) to ($3.22) per share. Conference CallConference Call TranscriptEarnings Press ReleaseEarnings Slide DeckPowered by RARE Upcoming EarningsUltragenyx Pharmaceutical's next earnings date is estimated for Thursday, May 1, 2025, based off prior year's reporting schedules. Get Ultragenyx Pharmaceutical Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ultragenyx Pharmaceutical and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataRARE Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.RARE Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ultragenyx Pharmaceutical Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$1.39-$1.07-$1.22Q2 20253-$1.32-$1.00-$1.14Q3 20253-$1.27-$0.85-$1.05Q4 20253-$1.18-$0.82-$0.99FY 202512-$5.16-$3.74-$4.40Q1 20261-$0.29-$0.29-$0.29 Ultragenyx Pharmaceutical Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/1/2025(Estimated)-------2/13/2025Q4 2024-$1.32-$1.39 -$0.07-$1.39$163.23M$164.88M11/5/2024Q3 2024-$1.45-$1.40+$0.05-$1.40$135.28M$139.49M8/1/2024Q2 2024-$1.64-$1.52+$0.12-$1.52$123.20M$147.03M5/2/2024Q1 2024-$1.72-$2.03 -$0.31-$2.03$116.03M$108.83M2/15/2024Q4 2023-$1.65-$1.52+$0.13-$1.52$119.38M$127.39M11/2/2023Q3 2023-$2.08-$2.23 -$0.15-$2.23$99.38M$98.05M8/3/2023Q2 2023-$2.11-$2.25 -$0.14-$2.25$107.10M$108.30M5/4/2023Q1 2023-$1.97-$2.33 -$0.36-$2.33$103.90M$100.50M Ultragenyx Pharmaceutical Earnings - Frequently Asked Questions When is Ultragenyx Pharmaceutical's earnings date? Ultragenyx Pharmaceutical has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 1st, 2025 based off last year's report dates. Learn more on RARE's earnings history. What guidance has Ultragenyx Pharmaceutical issued on next quarter's earnings? Ultragenyx Pharmaceutical updated its FY 2025 earnings guidance on Monday, January, 13th. The company issued revenue guidance of $640.0 million-$670.0 million, compared to the consensus revenue estimate of $638.4 million. Did Ultragenyx Pharmaceutical beat their earnings estimates last quarter? In the previous quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) missed the analysts' consensus estimate of ($1.32) by $0.07 with a reported earnings per share (EPS) of ($1.39). Learn more on analysts' earnings estimate vs. RARE's actual earnings. How can I listen to Ultragenyx Pharmaceutical's earnings conference call? The conference call for Ultragenyx Pharmaceutical's latest earnings report can be listened to online. Listen to Conference Call How can I read Ultragenyx Pharmaceutical's conference call transcript? The conference call transcript for Ultragenyx Pharmaceutical's latest earnings report can be read online. Read Transcript How much revenue does Ultragenyx Pharmaceutical generate each year? Ultragenyx Pharmaceutical (NASDAQ:RARE) has a recorded annual revenue of $560.23 million. How much profit does Ultragenyx Pharmaceutical generate each year? Ultragenyx Pharmaceutical (NASDAQ:RARE) has a recorded net income of -$569.18 million. RARE has generated -$6.34 earnings per share over the last four quarters. What is Ultragenyx Pharmaceutical's EPS forecast for next year? Ultragenyx Pharmaceutical's earnings are expected to grow from ($5.18) per share to ($3.22) per share in the next year. More Earnings Resources from MarketBeat Related Companies GMAB Earnings ITCI Earnings VTRS Earnings MRNA Earnings RDY Earnings PCVX Earnings SRPT Earnings QGEN Earnings ASND Earnings ROIV Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Hims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?Cirrus Logic Upgraded After Q3 Earnings Beat—More Gains Ahead? This page (NASDAQ:RARE) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RARE Stock Alerts